Investigational Drug Information for DCC-2618
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug DCC-2618?
DCC-2618 is an investigational drug.
There have been 29 clinical trials for DCC-2618.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2009.
The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Neoplasms, and Premature Birth. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, National Heart, Lung, and Blood Institute (NHLBI), and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Summary for DCC-2618
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 31 |
| WIPO Patent Applications | 48 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2009-10-01) |
| Vendors | 25 |
Recent Clinical Trials for DCC-2618
| Title | Sponsor | Phase |
|---|---|---|
| Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | Deciphera Pharmaceuticals LLC | Phase 1/Phase 2 |
| A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors. | Deciphera Pharmaceuticals LLC | Phase 1 |
| A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib | Zai Lab (Shanghai) Co., Ltd. | Phase 2 |
Clinical Trial Summary for DCC-2618
Top disease conditions for DCC-2618
Top clinical trial sponsors for DCC-2618
US Patents for DCC-2618
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
